Literature DB >> 23027562

Methodological concerns regarding cost-effectiveness analysis of palivizumab in Florida Medicaid.

Parthiv J Mahadevia, Doris Makari, Anthony Masaquel.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23027562     DOI： 10.1001/archpediatrics.2012.1591

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN： 1072-4710


× No keyword cloud information.
  3 in total

1.  Blocking Respiratory Syncytial Virus Entry: A Story with Twists.

Authors:  Marco Weisshaar; Robert Cox; Richard K Plemper
Journal:  DNA Cell Biol       Date:  2015-05-11       Impact factor: 3.311

2.  Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.

Authors:  Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

3.  Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.

Authors:  Jeong-Joong Yoon; Mart Toots; Sujin Lee; Myung-Eun Lee; Barbara Ludeke; Jasmina M Luczo; Ketaki Ganti; Robert M Cox; Zachary M Sticher; Vindya Edpuganti; Deborah G Mitchell; Mark A Lockwood; Alexander A Kolykhalov; Alexander L Greninger; Martin L Moore; George R Painter; Anice C Lowen; Stephen M Tompkins; Rachel Fearns; Michael G Natchus; Richard K Plemper
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.